Nature publishes new research on genetic causes of colorectal cancer
In the UK study, researchers analysed 2,023 bowel cancers from the 100,000 Genomes Project
Read More
Tag: colorectal cancer
ETH Zurich researchers reveal how colorectal cancer cells colonise the liver
Bowel cancer, the third most common cancer type worldwide, is the second most common cause of cancer death
Read More
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer
Immunotherapy regimen approved to treat metastatic colorectal cancer after prior chemotherapy
Read More
Keytruda wins NICE backing in MSI-H/dMMR colorectal cancer
Immunotherapy recommended for use in patients with MSI/dMMR biomarkers
Read More
NHS England makes Keytruda available for advanced colorectal cancer during pandemic
Interim treatment agreement reached for eligible patients during COVID-19 pandemic
Read More
Keytruda scores new EU approval in colorectal cancer
First checkpoint inhibitor to be approved in the EU to treat MSI-H or dMMR colorectal cancer
Read More
NICE backs Braftovi for BRAF-positive colorectal cancer
Positive recommendation follows initial rejection in September
Read More
NICE no for Pierre Fabre’s Braftovi
Preliminary guidelines reject NHS funding for the drug for BRAF V600E mutation-positive metastatic colorectal cancer
Read More
EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
Read More
Researchers develop new prognostic test for colorectal cancer
High-risk stage two cancer patients could be identified more easily and accurately, due to a hopeful new prognostic method developed by researchers at the University of St Andrews.
Read More
Pierre Fabre, Array showcase potential of triple therapy for CRC
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Read More
NICE expands reach of Erbitux in colorectal cancer
Cost regulators for the NHS treatments in England and Wales are expanding the scope of Merck’s Erbitux so that the therapy will be routinely available to treat a wider range of patients with metastatic colorectal cancer (mCRC).
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
